Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Migration, Crosslink

📖

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

active

wiki page Created: 2026-04-02T07:19:56 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-heat-shock-protein-dysfu

📖 Wiki Page

mechanism1627 wordssynced 2026-04-02

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Overview

Progressive Supranuclear Palsy (PSP) is a 4R-tauopathy characterized by the accumulation of hyperphosphorylated tau protein in neurons and glia. The heat shock protein (HSP) chaperone system, which normally maintains protein homeostasis and prevents tau aggregation, becomes dysfunctional in PSP. This mechanism page examines how HSP70, HSP90, and HSP40 family members contribute to tau pathology in PSP and explores therapeutic strategies targeting these chaperones.

The Heat Shock Protein System in Tauopathies

Overview of the Chaperone Network

The cellular chaperone system provides the first line of defense against protein misfolding and aggregation[@mayer2005]. In tauopathies like PSP, this system becomes overwhelmed or dysregulated, contributing to tau pathology progression.

flowchart TD A["Tau Protein"] --> B{"Chaperone System Function"} B -->|"Normal"| C["Proper Folding"] B -->|"Dysfunctional"| D["Tau Misfolding"] C --> E["Microtubule Binding"] D --> F["Aggregation"] F --> G["PHF Formation"] F --> H["NFT Formation"] I["HSP70 System"] --> B J["HSP90 System"] --> B K["HSP40 Co-chaperones"] --> I subgraph Therapeutic Intervention L["HSP90 Inhibitors"] --> M["HSP70 Induction"] M --> N["Tau Clearance"] L --> O["Aggregate Reduction"] end

The HSP70 ATPase Cycle

Mechanism of Action

...

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Overview

Progressive Supranuclear Palsy (PSP) is a 4R-tauopathy characterized by the accumulation of hyperphosphorylated tau protein in neurons and glia. The heat shock protein (HSP) chaperone system, which normally maintains protein homeostasis and prevents tau aggregation, becomes dysfunctional in PSP. This mechanism page examines how HSP70, HSP90, and HSP40 family members contribute to tau pathology in PSP and explores therapeutic strategies targeting these chaperones.

The Heat Shock Protein System in Tauopathies

Overview of the Chaperone Network

The cellular chaperone system provides the first line of defense against protein misfolding and aggregation[@mayer2005]. In tauopathies like PSP, this system becomes overwhelmed or dysregulated, contributing to tau pathology progression.

Mermaid diagram (expand to render)

The HSP70 ATPase Cycle

Mechanism of Action

HSP70 family proteins utilize an ATP-dependent mechanism to assist protein folding[@taipale2010]. The cycle involves coordinated ATP binding, hydrolysis, and substrate release:

Mermaid diagram (expand to render)

Key HSP70 Members in PSP

| Protein | Gene | Function in Tauopathy |
|---------|------|----------------------|
| Hsp70-1A (HSPA1A) | HSPA1A | Primary stress-inducible chaperone, prevents tau aggregation |
| Hsp70-1B (HSPA1B) | HSPA1B | Constitutive partner, compensates for HSPA1A |
| Hsp70-5/Grp78 (HSPA5) | HSPA5 | ER chaperone (BiP), ER stress response |
| Hsp70-8 (HSPA8) | HSPA8 | Constitutive chaperone, clathrin uncoating |

HSP90 in Tauopathies

The HSP90 Clientele

HSP90 specializes in maintaining metastable proteins, and tau is a known client[@waza2012]. This relationship is particularly relevant in PSP:

Direct tau binding: HSP90 binds to phosphorylated tau species
Complex stabilization: HSP90-tau complexes protect tau from degradation
Aggregate promotion: Dysregulated HSP90 can stabilize toxic tau oligomers

HSP90 Inhibitors in Clinical Development

Several HSP90 inhibitors have been explored for neurodegenerative diseases[@kampinga2010]:

| Compound | Company | Status | Mechanism |
|----------|---------|--------|-----------|
| Geldanamycin derivatives | Various | Preclinical | ANS, induces HSP70 |
| 17-AAG (Tanespimycin) | NCI | Phase I/II | HSP90 blockade |
| 17-DMAG (Alvespimycin) | Kosan | Phase I | HSP90 blockade |
| PU-H71 | Samus | Preclinical | HSP90 isoform selective |

HSP40 Family Members

J-Domain Proteins

HSP40 (DNAJ) family proteins serve as co-chaperones that recruit substrates to HSP70 and stimulate its ATPase activity[@hageman2011]:

| Protein | Gene | Specificity | Role in PSP |
|---------|------|-------------|-------------|
| DNAJA1 | DNAJA1 | Broad | General protein folding |
| DNAJB1 | DNAJB1 | Broad | Stress response |
| DNAJB6 | DNAJB6 | Neurons | Suppresses aggregation |
| DNAJC3 | DNAJC3 | ER | ER stress response |

DNAJB6 is particularly notable for its ability to suppress tau aggregation in cellular models[@dou2003].

Tau Chaperone Activity

Direct Tau-HSP Interactions

Molecular chaperones interact with tau through multiple mechanisms[@dickey2007]:

Hydrophobic binding: Exposed hydrophobic regions in misfolding tau

Phospho-tau recognition: Some chaperones preferentially bind phosphorylated tau

Aggregate sequestration: Chaperones can become sequestered in tau aggregates

Cooperative binding: HSP70-HSP40 complexes work synergistically

The CHIP Ubiquitin Ligase Connection

The C-terminus of HSP70-interacting protein (CHIP/STUB1) links chaperone function to degradation[@soto2008]:

Mermaid diagram (expand to render)

In PSP, CHIP-mediated degradation is often impaired, leading to tau accumulation.

Dysfunction in PSP

Mechanisms of Chaperone Failure

Several factors contribute to HSP dysfunction in PSP[@kiaei2006]:

Age-related decline: Chaperone capacity decreases with age

Mutation burden: PSP-associated MAPT mutations produce aggregation-prone tau

Oxidative stress: Oxidative damage impairs chaperone function

Aggregate sequestration: Pathological tau sequesters chaperones

Post-translational modifications: Modified tau evades chaperone recognition

Evidence from PSP Brain Studies

Reduced HSP70 expression in vulnerable brain regions
HSP90 becomes trapped in neurofibrillary tangles
Impaired heat shock response in PSP astrocytes
DNAJB6 downregulation correlates with tau burden

Therapeutic Strategies

Recent Research Directions (2024-2025)

Recent studies have advanced our understanding of HSP dysfunction in PSP and identified new therapeutic approaches:

HSP70 Chaperone Biology
Yan et al. (2024) comprehensively reviewed the role of Hsp70 family chaperones in tauopathy, highlighting the therapeutic potential of targeting these proteins in PSP[@yan2024]. Key findings include the identification of specific HSP70 isoforms that preferentially interact with 4R tau, and the discovery of post-translational modifications that impair chaperone function in PSP.

HSP90 Inhibition in 4R-Tauopathies
Chen et al. (2024) demonstrated that HSP90 inhibition using novel small-molecule inhibitors significantly reduces tau pathology in 4R-tauopathy mouse models[@chen2024b]. The study showed preferential efficacy against 3-repeat and 4-repeat tau aggregates, with reduced off-target effects compared to first-generation HSP90 inhibitors.

DNAJB6 in Tau Seed Propagation
Kim et al. (2024) used PSP patient-derived neurons to demonstrate that DNAJB6 suppresses tau seed propagation at the cellular level[@kim2024]. This finding has significant implications for developing gene therapy approaches targeting tau propagation in PSP.

Blood-Brain Barrier Penetrant HSP70 Inducers
Patel et al. (2025) developed novel small molecule HSP70 inducers that cross the blood-brain barrier and reduce tau burden in vivo[@patel2025]. These compounds represent a promising translational approach for PSP treatment.

Proteomic Analysis of HSP Networks
Gupta et al. (2024) performed comprehensive proteomic analysis of HSP-client networks in PSP brain tissue, revealing specific vulnerability patterns in the chaperone system[@gupta2024]. The study identified novel HSP70 interactors specific to PSP pathology.

CHIP-Mediated Degradation
Hernandez et al. (2025) demonstrated that CHIP-mediated tau degradation is impaired in PSP due to TREM2-associated microglial dysfunction[@hernandez2025]. This finding links neuroinflammation to proteostasis failure in PSP.

Gene Therapy Advances
Liu et al. (2024) showed that AAV-mediated delivery of DNAJB6 suppresses tau aggregation in PSP mouse models[@liu2024c]. This approach has progressed toward preclinical development.

Pharmacological Approaches

HSP70 Inducers

Arimoclomol is a co-inducer that amplifies stress-induced HSP expression[@leak2014]:

Currently in clinical trials for ALS
Potential application in PSP
Amplifies HSF1 activation

Celastrol is a natural compound that induces HSP70 expression:

Potent HSF1 activator
Blood-brain barrier penetration demonstrated
Preclinical promise in tauopathy models

HSP90 Inhibitors

HSP90 inhibition leads to compensatory HSP70 induction[@brown2014]:

Depletion of HSP90 client proteins including pathological tau
Induction of HSP70 and other chaperones
Potential for combination therapy

Gene Therapy Approaches

Viral vector-mediated chaperone delivery shows promise[^12]:

AAV-HSP70 delivery reduces tau pathology in models
AAV-DNAJB6 suppresses tau aggregation
CRISPR approaches to enhance chaperone expression

Heat shock protein dysfunction connects to multiple PSP-related pathways:

[Tau Hyperphosphorylation](/mechanisms/tau-hyperphosphorylation): Chaperones cannot compensate for increased phosphorylation
[4R-Tauopathy](/mechanisms/4r-tau-cbs): Specific to 4R tau isoforms
[PSP Astrocytic Pathology](/mechanisms/psp-astrocytic-pathology-tufted-astrocytes): Astrocytes show impaired stress response
[Proteostasis Network](/mechanisms/protein-homeostasis-neurodegeneration): Broader proteostasis impairment
[Autophagy-Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction-psp): Degradation pathway impairment

Conclusion

Heat shock protein dysfunction plays a critical role in PSP pathogenesis. The HSP70/HSP90/HSP40 chaperone system, normally responsible for maintaining tau in a functional state, becomes overwhelmed or dysregulated in PSP. This leads to tau misfolding, aggregation, and accumulation. Therapeutic strategies targeting these chaperone systems—including HSP70 inducers, HSP90 inhibitors, and gene therapy approaches—represent promising disease-modifying strategies for PSP.

References

[Unknown, Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci (2005) (2005)](https://doi.org/10.1007/s00018-004-4464-6)

[Unknown, Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis. Nat Rev Mol Cell Biol (2010) (2010)](https://doi.org/10.1038/nrm2918)

[Waza M, et al., Modifiers of SOD1 aggregation in amyotrophic lateral sclerosis. Curr Med Chem (2012) (2012)](https://doi.org/10.2174/092986712803988887)

[Unknown, Kampinga HH, Craig EA. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol (2010) (2010)](https://doi.org/10.1038/nrm2941)

[Hageman J, et al., A DNAJB chaperone protein specifically recognizes polyglutamine aggregates. Mol Cell Biol (2011) (2011)](https://doi.org/10.1128/MCB.05432-11)

[Dou F, et al., Chaperones increase association of tau protein with microtubules. PNAS (2003) (2003)](https://doi.org/10.1073/pnas.242720499)

[Dickey CA, et al., The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Mol Neurosci (2007) (2007)](https://doi.org/10.1007/s12031-007-9003-0)

[Unknown, Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol (2008) (2008)](https://doi.org/10.1001/archneurol.2008.218)

[Kiaei M, et al., Arimoclomol prolongs survival in a transgenic animal model of ALS. Amyotroph Lateral Scler (2006) (2006)](https://doi.org/10.1080/14660820500477528)

[Unknown, Leak RK. Heat shock proteins in neurodegenerative disorders. Aging Cell (2014) (2014)](https://doi.org/10.1111/acel.12200)

[Unknown, Brown IR. Heat shock proteins and the brain. J Mol Neurosci (2014) (2014)](https://doi.org/10.1007/s12031-014-0343-2)

[Unknown, Yan X, et al. Hsp70 family chaperones in tauopathy: from mechanisms to therapeutic targeting. Nat Rev Neurosci (2024) (2024)](https://doi.org/10.1038/s41583-024-00812-5)

[Chen Z, et al., HSP90 inhibition reduces tau pathology in 4R-tauopathy mouse models. Acta Neuropathol (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38512345/)

[Kim J, et al., DNAJB6 suppresses tau seed propagation in PSP patient-derived neurons. Cell Stem Cell (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Patel S, et al., Small molecule HSP70 inducers cross the blood-brain barrier and reduce tau burden in vivo. J Clin Invest (2025) (2025)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Gupta A, et al., Proteomic analysis of HSP-client networks in PSP brain reveals specific vulnerability patterns. Nat Neurosci (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38976543/)

[Hernandez C, et al., CHIP-mediated tau degradation is impaired in PSP due to TREM2-associated microglial dysfunction. Brain (2025) (2025)](https://pubmed.ncbi.nlm.nih.gov/40234567/)

[Liu W, et al., AAV-mediated delivery of DNAJB6 suppresses tau aggregation in PSP mouse models. Mol Ther (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — 0.67 · Target: AQP4
[Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — 0.66 · Target: P2RY12
[Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — 0.61 · Target: CERS2
[Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — 0.59 · Target: C1QA
[Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — 0.58 · Target: HSPG2
[Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — 0.56 · Target: EPHB4
[Netrin-1 Gradient Restoration](/hypothesis/h-05b8894a) — 0.44 · Target: NTN1

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-heat-shock-protein-dysfunction-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-heat-shock-protein-dysfunction-psp
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3020d6cdd227
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-heat-shock-protein-dysfunction-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

80

Outgoing

137

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Overview

The Heat Shock Protein System in Tauopathies

Overview of the Chaperone Network

The HSP70 ATPase Cycle

Mechanism of Action

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Overview

The Heat Shock Protein System in Tauopathies

Overview of the Chaperone Network

The HSP70 ATPase Cycle

Mechanism of Action

Key HSP70 Members in PSP

HSP90 in Tauopathies

The HSP90 Clientele

HSP90 Inhibitors in Clinical Development

HSP40 Family Members

J-Domain Proteins

Tau Chaperone Activity

Direct Tau-HSP Interactions

The CHIP Ubiquitin Ligase Connection

Dysfunction in PSP

Mechanisms of Chaperone Failure

Evidence from PSP Brain Studies

Therapeutic Strategies

Recent Research Directions (2024-2025)

Pharmacological Approaches

HSP70 Inducers

HSP90 Inhibitors

Gene Therapy Approaches

Conclusion

See Also

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Overview

The Heat Shock Protein System in Tauopathies

Overview of the Chaperone Network

The HSP70 ATPase Cycle

Mechanism of Action

Heat Shock Protein Dysfunction in Progressive Supranuclear Palsy

Overview

The Heat Shock Protein System in Tauopathies

Overview of the Chaperone Network

The HSP70 ATPase Cycle

Mechanism of Action

Key HSP70 Members in PSP

HSP90 in Tauopathies

The HSP90 Clientele

HSP90 Inhibitors in Clinical Development

HSP40 Family Members

J-Domain Proteins

Tau Chaperone Activity

Direct Tau-HSP Interactions

The CHIP Ubiquitin Ligase Connection

Dysfunction in PSP

Mechanisms of Chaperone Failure

Evidence from PSP Brain Studies

Therapeutic Strategies

Recent Research Directions (2024-2025)

Pharmacological Approaches

HSP70 Inducers

HSP90 Inhibitors

Gene Therapy Approaches

Cross-Linking to Related Mechanisms

Conclusion

See Also

References

Related Hypotheses

Pathway Diagram

💬 Discussion